Drug name - Esbriet

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7988994 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients Sep, 2026

(3 years from now)

US7767225 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients Sep, 2026

(3 years from now)

US8753679 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients Sep, 2026

(3 years from now)

US8383150 GENENTECH INC Granulate formulation of pirfenidone and pharmaceutically acceptable excipients Sep, 2026

(3 years from now)

US7767700 GENENTECH INC Method of providing pirfenidone therapy to a patient Dec, 2027

(5 years from now)

US7696236 GENENTECH INC Method of providing pirfenidone therapy to a patient Dec, 2027

(5 years from now)

US8420674 GENENTECH INC Method of providing pirfenidone therapy to a patient Dec, 2027

(5 years from now)

US7635707 GENENTECH INC Pirfenidone treatment for patients with atypical liver function Apr, 2029

(6 years from now)

US8592462 GENENTECH INC Pirfenidone treatment for patients with atypical liver function Apr, 2029

(6 years from now)

US7566729 GENENTECH INC Modifying pirfenidone treatment for patients with atypical liver function Apr, 2029

(6 years from now)

US8609701 GENENTECH INC Pirfenidone treatment for patients with atypical liver function Apr, 2029

(6 years from now)

US7816383 GENENTECH INC Methods of administering pirfenidone therapy Jan, 2030

(7 years from now)

US8084475 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450 Jan, 2030

(7 years from now)

US8318780 GENENTECH INC Methods of administering pirfenidone therapy Jan, 2030

(7 years from now)

US8754109 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450 Jan, 2030

(7 years from now)

US8648098 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450 Jan, 2030

(7 years from now)

US8013002 GENENTECH INC Methods of administering pirfenidone therapy Jan, 2030

(7 years from now)

US7910610 GENENTECH INC Methods of administering pirfenidone therapy Jan, 2030

(7 years from now)

US8778947 GENENTECH INC Methods of administering pirfenidone therapy Aug, 2033

(10 years from now)

US10188637 GENENTECH INC Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same Mar, 2037

(14 years from now)

Drugs and Companies using PIRFENIDONE ingredient

Treatment: Method of administering pirfenidone capsules to treat a fibrotic condition; Method of administering a granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone as recited in claim 1, to treat idiopathic pulmonary fibrosis; Pirfenidone dose escalation regimen for treatment of ipf as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen; Dose escalation over 14 days for treatment of idiopathic pulmonary fibrosis; Dose escalation over 14 days for treatment of a fibrosis condition; Continued dosing or dosage modification following elevated liver enzymes in treatment of idiopathic pulmonary fibrosis; Dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, then at least 1600mg/day in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits, followed by administering at least 1600 mg/day in treatment of ipf; dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by administering sub-1600 mg/day, following by administering at least 1600 mg/day in treatment of ipf; dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by administering sub-2400mg/day dose, followed by administering 2403mg/day in treatment of ipf; dosing 2403 mg/day pirfenidone following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by administering sub-1600 mg/day dose, followed by administering at least 1600 mg/day dose in treatment of ipf; dosing of at least 1600 mg/day following grade 2 liver abnormality in biomarker ast and/or alt after pirfenidone administration in treatment of ipf; dosing of at least 1600 mg/day following grade 2 abnormality in liver function biomarker after pirfenidone administration in treatment of ipf; dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, followed by full daily dose in treatment of ipf; Dosage modification following elevated liver enzymes in treatment of idiopathic pulmonary fibrosis; Continued dosing or dosage modification following elvated liver enzymes in use of pirfenidone; Discontinuing administration of fluvoxamine to avoid drug interactions with pirfenidone and then administering pirfenidone; administering pirfenidone while avoiding co-administration of fluvoxamine to avoid drug interactions with pirfenidone; Method for administering pirfenidone to avoid reduced efficacy by discontinuing smoking or by discontinuing or avoiding another strong cyp1a2 inducer; Method for administering pirfenidone while avoiding or discontinuing concomitant use of a moderate to strong inhibitor of both cyp1a2 and another cyp enzyme involved in pirfenidone metabolism; Method for administering pirfenidone to avoid reduced efficacy by avoiding smoking or by avoiding another strong cyp1a2 inducer; Method for administering pirfenidone to avoid reduced efficacy by discontinuing smoking or by discontinuing a strong cyp1a2 inducer; Method for administering pirfenidone to reduce drug interactions with fluvoxamine; Administering pirfenidone while avoiding co-administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone; discontinuing administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone and then administering pirfenidone; Dose reduction of pirfenidone by about one half during concurrent administration of ciprofloxacin at a dose of 750 mg twice daily (1500 mg/day) to reduce drug interactions in treatment of a fibrotic, inflammatory, or autoimmune disorder; administration of pirfenidone and avoiding concurrent administration of ciprofloxacin at a dose of 750 mg to reduce drug interactions in treatment of a fibrotic, inflammatory, or autoimmune disorder

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
267MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.